This article was written by

Analyst’s Disclosure: I/we have a beneficial long position in the shares of RGLD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

ET Intelligence Group: Pharmaceuticals and healthcare companies are set for a mixed March-quarter. Hospital chains are expected to deliver steady growth while generic drugmakers face pressure from the absence of Revlimid-related sales and pricing headwinds. Lupin is expected to deliver strong growth in revenue, margin and profit, while Divi’s is likely to benefit from improving contract development demand and operating leverage. Sun Pharma and Torrent are expected to post steady growth led by diversified portfolios and domestic strength, while Apollo Hospitals may see resilient traction across hospitals, pharmacy and diagnostics.

Sun Pharma is expected to benefit from strong momentum in India and Europe with incremental improvement in the US led by specialty products. New launches and a higher specialty contribution are expected to support growth while margins face sequential pressure from higher research and development (R&D) spends.

Aurobindo Pharma is likely to report single-digit revenue growth supported by steady performance across regions other than the US where sales are likely to fall by 10% due to slack in gRevlimid sales. Europe may grow in double-digits driven by higher biosimilars sales. The operating profit before depreciation and amortisation (Ebitda) is expected to remain flat while Ebitda margin may decline by 80-100 basis-points (bps). Key monitorables include ramp-up at the 6-APA plant and resolution of USFDA observations at Eugia facilities.

Dr Reddy’s will be another company to be affected by reduced business of gRevlimid following patent expiry and one-time impact of shelf stock adjustments. Its India business is likely to fare better, supported by strong traction in pain, respiratory and gastro segments. Ebitda could decline 28-30% with around 600 bps of margin contraction. Key monitorables include semaglutide progress in Canadian market and brand litigation with Novo Nordisk for semaglutide products in India.

Lupin’s US revenue is expected to be strong driven by traction in Tolvaptan, Mirabegron, g-Spiriva and Glucagon, partly offset by Albuterol pricing pressure. Domestic sales are likely to grow in double-digits, driven by higher focus on chronic therapies, while emerging markets are expected to drive growth. Ebitda is projected to jump around 50% year-on-year. The margin may decline sequentially due to higher R&D spends, elevated marketing costs and absence of PLI income.

Cipla‘s sales are expected to decline as the US market faces higher competition in g-Revlimid business and lower Lanreotide sales following supply disruptions. Its India business is expected to be driven by respiratory and anti-diabetic therapies, offset by subdued performance in pain. Ebitda is expected to fall 32-38% with margins contracting by 700-800 bps, reflecting lower US contribution and pressure on gross margins.
Apollo Hospitals revenue growth to be supported by steady performance across segments. The hospitals segment sales growth could be in double-digits, aided by new bed additions and increase in average revenue per patient. HealthCo revenue is projected to grow in high double-digits, driven by strong offline pharmacy sales, while the Ebitda loss of Apollo 24/7 may narrow. Consolidated Ebitda is expected to rise in double-digits with margin likely to grow by 50 bps. Torrent Pharma’s revenue is likely to rise in high double-digits, led by consolidation of JB Pharma from January 2026 and steady organic growth. Divi’s Laboratories revenue is expected to grow in double-digits on a year-on-year and sequential basis, driven by strong momentum in custom synthesis (CS) and a low-base nutraceuticals recovery. However, generic API sales are likely to decline year-on-year, despite a sequential rebound, reflecting pricing pressure.

NEW YORK — Investors weighing whether to buy or sell Palantir Technologies stock in 2026 face a classic growth-versus-valuation debate as the data analytics powerhouse, trading near $144, heads into its first-quarter earnings report Monday with strong commercial AI momentum but a premium multiple that has some analysts urging caution. Wall Street’s consensus leans Moderate Buy, with an average 12-month price target around $192 implying roughly 33 percent upside, though skeptics highlight risks from competition and stretched valuations.

Palantir’s Artificial Intelligence Platform (AIP) continues driving accelerating commercial revenue, with analysts projecting Q1 revenue of approximately $1.53-1.54 billion, up about 74 percent year-over-year. Adjusted earnings per share are expected near $0.28, more than doubling from the prior year. The company has consistently beaten expectations, fueling optimism about its position in enterprise AI deployment.

Recent analyst actions reflect divided but generally positive sentiment. Citi set a Street-high target of $260 before trimming slightly to $210, while Oppenheimer initiated coverage with an Outperform rating and $200 target. UBS and Daiwa upgraded to Buy with $180 targets earlier in the year. However, HSBC downgraded to Hold citing emerging competition, and some voices warn of potential post-earnings volatility if guidance fails to excite.

The bull case centers on Palantir’s expanding commercial footprint and sticky government contracts. U.S. commercial revenue is forecasted to surge more than 100 percent in some projections, with the company adding high-profile clients and demonstrating strong bookings. Proponents argue that Palantir’s platform is becoming essential infrastructure for AI adoption, justifying premium multiples as revenue scales and margins expand.

Valuation remains the primary bear-case concern. Palantir trades at forward price-to-sales multiples above 40x and price-to-earnings exceeding 200x in some estimates. Critics note that even impressive growth may not sustain such levels if broader AI hype cools or if competitors offer similar capabilities at lower prices. A deeper pullback could test support near $100-$110 if earnings disappoint.

For long-term investors, Palantir represents exposure to secular AI tailwinds. The company’s dual commercial and government business provides diversification, while its focus on agentic AI and data integration differentiates it from pure-play software firms. Analysts forecasting 2026 year-end prices often see shares between $175 and $230, with optimistic models reaching higher on sustained 50-60 percent growth.

Short-term traders should monitor Monday’s report closely. Strong commercial metrics and raised full-year guidance could spark a rally, while any softening in deal velocity might trigger profit-taking. Implied volatility suggests potential double-digit moves post-earnings.

Portfolio fit matters. Growth-oriented investors comfortable with volatility may view current levels as an entry point into a multi-year AI winner. Value-focused or conservative accounts might wait for a better entry or allocate smaller positions. The stock’s beta indicates sensitivity to broader tech sentiment and macroeconomic shifts.

Palantir has evolved from a primarily government contractor to a diversified AI software leader. Its boot camp sales approach and platform stickiness have driven accelerating growth, but execution risks remain as the company scales rapidly. Management’s track record of under-promising and over-delivering provides some buffer.

Broader market context influences the outlook. With interest rates and AI spending trends in focus, Palantir benefits from corporate digitization but could face headwinds in a slowdown. Geopolitical factors may support government revenue, while commercial expansion depends on economic health.

Analyst dispersion is wide, with targets ranging from $50 to $255. The Moderate Buy consensus reflects confidence in fundamentals tempered by valuation discipline. Long-term forecasts for 2026 year-end prices cluster in the $190-$220 range under base-case scenarios.

Ultimately, buying Palantir in 2026 suits those believing in its AI platform’s durable competitive moat and growth runway. Selling or avoiding appeals to those prioritizing valuation or fearing competition. Holding through volatility has rewarded patient investors historically, but new positions warrant careful sizing given the premium pricing.

As earnings loom, the market will render its verdict on Palantir’s trajectory. The company’s ability to deliver commercial acceleration while maintaining discipline will shape investor conviction for the remainder of 2026 and beyond. For now, the data points to continued upside potential for believers in its long-term vision.